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ABSTRACT
Objectives Blockade of transient receptor potential
vanilloid 1 (TRPV1) with systemic antagonists attenuates
osteoarthritis (OA) pain behaviour in rat models, but
on-target-mediated hyperthermia has halted clinical
trials. The present study investigated the potential for
targeting TRPV1 receptors within the OA joint in order
to produce analgesia.
Methods The presence of TRPV1 receptors in human
synovium was detected using western blotting and
immunohistochemistry. In a rat model of OA, joint levels
of an endogenous ligand for TRPV1, 12-hydroxy-
eicosatetraenoic acid (12-HETE), were quantiﬁed using
liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Effects of peripheral administration of the
TRPV1 receptor antagonist JNJ-17203212 on afferent
ﬁbre activity, pain behaviour and core body temperature
were investigated. Effects of a spinal administration of
JNJ-17203212 on dorsal horn neuronal responses were
studied.
Results We demonstrate increased TRPV1
immunoreactivity in human OA synovium, conﬁrming
the diseased joint as a potential therapeutic target for
TRPV1-mediated analgesia. In a model of OA pain,
we report increased joint levels of 12-HETE, and the
sensitisation of joint afferent neurones to mechanical
stimulation of the knee. Local administration of JNJ-
17203212 reversed this sensitisation of joint afferents
and inhibited pain behaviour (weight-bearing
asymmetry), to a comparable extent as systemic JNJ-
17203212, in this model of OA pain, but did not alter
core body temperature. There was no evidence for
increased TRPV1 function in the spinal cord in this
model of OA pain.
Conclusions Our data provide a clinical and
mechanistic rationale for the future investigation of the
therapeutic beneﬁts of intra-articular administration of
TRPV1 antagonists for the treatment of OA pain.
INTRODUCTION
Osteoarthritis (OA), a degenerative disease of syn-
ovial joints, is a major cause of pain and physical dis-
ability.1 2 OA pain arises partly from altered sensory
processing in the joint,3 4 as indicated by analgesic
effects of intra-articular local anaesthetics, and
lowered peripatellar pressure pain thresholds.5 6
The identiﬁcation of substrates underpinning the
sensitisation of sensory afferents innervating the OA
joint may provide new targets for treatments which
prevent, or delay, the progression of OA pain.
The pronociceptive non-selective cation channel
transient receptor potential vanilloid 1 (TRPV1)
plays important roles in the detection of noxious
stimuli and inﬂammatory hyperalgesia.7 TRPV1 has
been implicated in OA pain, both in animal
models8–11 and by the ﬁnding that TRPV1 genetic
variants are associated with the risk of symptomatic
knee OA in humans.12 TRPV1 is enriched in small
diameter cell bodies of nociceptive nerve ﬁbres that
innervate the articular capsule of the joint and is
upregulated in the sensory afferent ﬁbres innervat-
ing the OA joint.13
Clinical trials of oral TRPV1 antagonists have
been limited by on-target-induced hyperthermia,14
which is also apparent in rodents15 16 and attribu-
ted to effects on the gastrointestinal system.17–19
Identiﬁcation of the contribution of local knee
joint, versus central, sites of action to the analgesic
effects of TRPV1 antagonists in OA may provide
novel approaches by which TRPV1 targeted anal-
gesia can be achieved in the absence of side effects.
Here we quantify levels of TRPV1 protein in
human OA synovium, inﬂammatory rheumatoid
arthritis (RA) synovium and postmortem (PM) con-
trols and test the hypothesis that joint TRPV1 con-
tributes to altered sensory inputs from the OA
joint. Finally, we determine whether blockade of
knee joint TRPV1 attenuates OA pain responses in
the absence of hyperthermic side effects.
METHODS
Subjects
We used synovial tissue from people undergoing
total knee joint replacement (TKR) for OA (n=27)
or RA (n=8) and PM knees from seven people
without history of knee pain and with no macro-
scopic evidence of arthritis. Median age of partici-
pants was 68 (IQR 64–77) years). Human tissue
collection followed informed consent from the
donor or next of kin according to protocols
approved by the North Nottinghamshire local
research ethics committee (NNHA/420, NNHA/
544 and NNHA/673).
Animals
Experiments were conducted on male Sprague–
Dawley rats (160–190 g; Charles River, UK) in
accordance with the Animal (Scientiﬁc Procedures)
Act 1986 and ARRIVE guidelines. A total of 176
rats were used.
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Assessment of hyperthermia
Under isoﬂurane anaesthesia, rats received an intra-articular
injection of the TRPV1 antagonist JNJ-17203212 (1 mg/50 mL,
n=6) or vehicle (3% Tween 80 in saline, 0.5% ethanol (EtOH),
n=6). As a positive control,20 a separate cohort of rats received
oral JNJ-17203212 (10.6 mg/1.05 mL, n=6) or vehicle (poly-
ethylene glycol 400, n=6). Rectal temperature was measured up
to 4 h post-drug administration.
MIA-induced OA and pain assessment
The mono-iodoacetate (MIA) model, which mimics common fea-
tures of human OA joint pathology and is associated with robust
pain behaviour21 22 was generated as previously described (see
online supplemental methods).22 Pain responses were assessed as
previously described,22 weight-bearing is presented as (weight on
contralateral limb—weight on ipsilateral limb)/total weight on
limbs×100) and weight-bearing asymmetry is indicative of
hyperalgesia.23 Changes in hind paw mechanical withdrawal
thresholds were assessed using von Frey (vF) monoﬁlaments
(Linton Instrumentation, bending forces 1–26g) as previously
described.22 Rats were tested on days 0 and 3–28 post-injection.
Effects of intra-articular and systemic (intra-peritoneal (i.p))
injection of the TRPV1 antagonist JNJ-17203212 (1 mg/50 μL
and 1 mg/300 μL, respectively, based on published studies20;
Tocris, UK; n=11/7 rats), or vehicle (3%Tween 80 in saline,
0.5% EtOH; n=9/6 rats), on weight-bearing and hind paw
withdrawal thresholds were assessed in MIA-treated rats at
14 days post-model induction; a time point associated with joint
afferent sensitisation.24
Measurement of 12-HETE by LC-MS/MS analysis
Rats were humanely killed and knee joints, dorsal root ganglia
(DRG) and spinal cord were rapidly dissected and stored at
−80°C. The liquid chromatography-tandem mass spectrometry
(LC-MS/MS) method employed is based on,25 see online sup-
plemental methods.
TaqMan quantitative real-time PCR (RT-PCR)
Rats were humanely killed and knee joint synovium was rapidly
dissected and embedded in optimal cutting temperature (OCT)
compound. The real-time PCR (RT-PCR) method employed was
based on,22 see online supplemental methods.
Joint afferent recordings
At 14 days following injection of MIA (n=30) or saline (n=37)
rats were anaesthetised (sodium pentobarbital) and prepared for
joint afferent recordings.24 Action potentials were recorded
from two to three identiﬁable ipsilateral saphenous nerve ﬁla-
ments (Spike2 software, Cambridge Electronic Design (CED),
Cambridge, UK) and ﬁring rates of the most reliable single ﬁbre
were quantiﬁed.24 Mechanically evoked responses (the mean
frequency of ﬁring) of ﬁbres following application of vFs (0.16–
15g/5 s each) to subcutaneous structures over and around the
knee joint were recorded. Thresholds and conduction velocities
were calculated as described.24 Conduction velocities ranged
from 0.31 to 13.4 m/s encompassing C-ﬁbres and Aδ-ﬁbres
(n=67; one ﬁbre studied per rat).
The TRPV1 antagonist JNJ-17203212 (0.075, 0.15 mg/
100 μL), the TRPV1 agonist capsaicin (5, 10 μM/100 μL) or
vehicle (100 μL 2.5, 5% ethanol/Tween 80 in saline) was admi-
nistered by close intra-arterial administration via a right femoral
artery cannula with the tip located at the bifurcation of the
descending aorta24 and mechanically evoked responses were
assessed every 5 min for 60 min/dose.
Spinal neuronal recordings
Rats were prepared as previously described.22 A sharp glass-
coated tungsten microelectrode was inserted into the dorsal
horn of the spinal cord. Wide dynamic range (WDR) neurones
with a receptive ﬁeld over the ipsilateral hind paw were
recorded (depth 500–1000 mm from the cord surface). vF
monoﬁlaments (8, 10, 15, 26 and 60 g) were applied to the
centre of the receptive ﬁeld and evoked responses recorded.
Effects of topical spinal administration of the TRPV1 antagonist
JNJ-17203212 (18.75, 37.5 and 75 mg/50 mL) at 50 min inter-
vals (n=7–9) or three equivalent doses of 50 mL vehicle (n=7)
on evoked responses were recorded.
Immunohistochemistry
Immunohistochemistry26 with an afﬁnity-puriﬁed rabbit poly-
clonal antibody directed against human TRPV1 (SC-20813,
Santa Cruz Biotechnology Inc.) was conducted on synovial sec-
tions from patients with OA (n=9; three men/six women), RA
(n=8; two men/six women) and PM controls (n=7; six men/
one woman). TRPV1 and macrophage (CD68) immunoreactiv-
ities in synovial sections from arthritic human (n=6) were colo-
calised by double immunoﬂuorescence (see online supplemental
methods). TRPV1 fractional area was deﬁned as the percentage
of synovial tissue section area (within 200 μm of the synovial
surface) occupied by TRPV1 immunoreactivity. Quantiﬁcation
was undertaken in a blinded fashion with computer-assisted
image analysis as described previously.26 Rat spinal cord sections
from MIA- and saline-treated rats (n=5/group) (see online sup-
plemental methods) were incubated with a polyclonal guinea
pig anti-TRPV1 antibody (1 : 500, Neuromics, Edina,
Minnesota, USA catalogue number GP14100) and then with
Alexa 568-conjugated goat anti-guinea pig secondary antibody
(1:300, Molecular Probes). TRPV1 immunostaining was visua-
lised with a Leica DMRB/DM4000 B ﬂuorescence microscope
and images were acquired using Openlab software
(PerkinElmer). Quantiﬁcation with Velocity V.5.5 software
(Perkin Elmer, UK) used a minimum of ﬁve sections per rat.
Negative controls (primary antibodies omitted) were included
to conﬁrm speciﬁcity of detected immunoreactivities.
Western blotting
Membrane-enriched fractions of OA synovial samples (n=18
patients) were prepared. Samples were homogenised in 2 mL
NaCl-EDTA-Tris (NET) buffer (150 mM NaCl, 3 mM EDTA,
50 mM Tris, pH 7.4) containing 50 mL protease inhibitor cock-
tail (comprised of 4-(2-aminoethyl)benzenesulfonyl ﬂuoride,
pepstatin A, E-64, bestatin, leupeptin and aprotinin) and ultra-
centrifuged (1000×g, 10 min, 4°C). Membrane-enriched frac-
tions were pelleted from the supernatant by ultracentrifugation
(100 000×g, 30 min, 4°C) and resuspended in 200 mL NET
buffer plus 0.5% triton x-100. One hundred microlitres of
samples were separated on a 7.5% polyacrylamide gel and trans-
ferred to polyvinylidene diﬂuoride membrane and exposed to
anti-human TRPV1 for 24 h at 4°C and then a goat anti-rabbit
horseradish peroxidase conjugate secondary antibody (PI-1000,
Vector Laboratories, Cambridge, UK). The enhanced chemilu-
minescent (ECL) chemiluminescence kit was used to detect
immunoreactivity by exposure to autorads.
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Data and statistical analysis
Analysis was performed using Prism V.5 (Graphpad Software,
San Diego, California, USA) and normality assessed (D’Agostino
& Pearson normality test) prior to statistical analysis. t Tests
compared two groups of data and analysis of variance (ANOVA)
with Bonferroni’s post hoc test compared more than two groups
when normality was achieved. Non-parametric tests,
Mann-Whitney (two groups) and Kruskal–Wallis with Dunn’s
post hoc test (more than two groups) were used when normality
was not obtained. Behavioural, electrophysiological and spinal
cord immunohistochemistry data are presented as mean±SEM.
RESULTS
Increased expression of TRPV1 in human synovium
TRPV1 immunoreactivity was present in OA (ﬁgure 1A), RA
and PM synovium and was predominantly localised to mono-
nuclear cells within the synovial lining region, but was also
within the deeper layers of the synovium where macrophages
were abundant. The majority of TRPV1 immunoreactivity was
localised to CD68-positive macrophages (ﬁgure 1A,B). TRPV1
fractional areas differed between disease groups (χ2=12.0,
p=0.003, ﬁgure 1C). TRPV1 fractional areas were lowest in PM
synovium (median 0.0%, IQR 0.0–3.3%) compared with
patients with OA (median 7.3%, IQR 5.9–9.2%, Z=−2.9,
p=0.004) or RA (median 5.2%, IQR 4.5–7.5%, Z=−2.6,
p=0.01, ﬁgure 1C). The absence of staining in the negative
control conﬁrmed speciﬁcity of detected immunoreactivity.
Membrane-enriched synovial samples from 12 (67%) of 18 OA
patients displayed detectable TRPV1 immunoreactivity in the
100 kDa region (ﬁgure 1D), consistent with the reported
molecular weight for TRPV1.27
Intra-articular administration of a TRPV1 antagonist inhibits
pain behaviour in the MIA model of OA pain
The next series of experiments used an experimental model of
OA pain to investigate the potential contribution of joint
TRPV1 to OA pain. Following intra-articular injection of MIA,
rats exhibited a signiﬁcant weight-bearing asymmetry and a sig-
niﬁcant decrease in hindlimb withdrawal thresholds compared
with saline-treated rats (see online supplementary ﬁgure S1).
Intra-articular injection of the TRPV1 antagonist JNJ-17203212
signiﬁcantly attenuated MIA-induced weight-bearing asymmetry
(ﬁgure 2A) compared with MIA-treated rats receiving vehicle
and to a similar degree as that seen following systemic
JNJ-17203212 (ﬁgure 2A). Unlike systemic JNJ-17203212,
intra-articular JNJ-17203212 did not signiﬁcantly alter distal
allodynia (see online supplementary ﬁgure S2) in MIA-treated
rats. Intra-articular injection of JNJ-17203212 did not alter core
body temperature (baseline=37.08±0.35°C; 0.5 h=36.98
±0.40°C, 2 h=37.42±0.11°C) compared with vehicle-treated
rats (baseline=37.37±0.10°C; 0.5 h=36.90±1.2°C, 2 h=37.30
±0.12°C). Note systemic administration of JNJ-1720312 signiﬁ-
cantly elevated core body temperature as previously described
(see online supplementary data).
Is there a functional upregulation of TRPV1 in the joint in
the MIA model of OA pain?
In order to focus on the potential role of TRPV1 within the
knee joint, we ﬁrst quantiﬁed levels of a known ligand for
TRPV1 (12-hydroxy-eicosatetraenoic acid (12-HETE)) in the
knee joint and cell bodies of the afferent ﬁbres (DRGs) in
MIA-treated rats. 12-HETE was quantiﬁed (see online supple-
mentary ﬁgure S3) in all the rat knee joints and DRG samples
analysed. Levels of 12-HETE were signiﬁcantly higher in the
joint tissue of MIA-treated rats compared with saline-treated
rats (p<0.05, ﬁgure 2B). These changes were restricted to the
joint as levels of 12-HETE in the DRGs were comparable
between MIA-treated and saline-treated rats (median:
MIA=0.35 pmol/g, range=0.17–1.18 pmol/g; saline=0.23
pmol/g; range=0.07–0.55 pmol/g). TRPV1 mRNA was present
in rat synovium expressed at levels that were comparable
between saline-treated and MIA-treated rats when adjusted for
the housekeeping gene β-actin (see online supplementary ﬁgure
S4). Given that TRPV1 mRNA expression in synovium is on
inﬁltrating mononuclear cells (eg, macrophages), when levels are
adjusted for β-actin, no increase in expression is consistent with
increased abundance.
The next experiments investigated whether TRPV1 contri-
butes to the sensitisation of knee joint afferents in the MIA
model of OA pain. Mechanically evoked responses of knee joint
afferents were signiﬁcantly increased (ﬁgure 2C) and mechanical
thresholds were signiﬁcantly lower in MIA-treated rats (n=30
ﬁbres) compared with saline-treated rats (n=37 ﬁbres) (see
online supplementary ﬁgure S5). Intra-arterial administration of
the TRPV1 agonist capsaicin (5, 10 μM/100 μL) close to the
ipsilateral knee joint signiﬁcantly increased mechanically evoked
responses (ﬁgure 2D; p<0.001, two-way ANOVA) and reduced
mechanical thresholds (ﬁgure 2E, Mann–Whitney, p<0.05) of
ﬁbres in saline-treated rats, but not MIA-treated rats (data not
shown). Intra-arterial administration of the TRPV1 antagonist
Figure 1 Transient receptor potential vanilloid 1 (TRPV1) and CD68
immunoreactivities in human synovium. TRPV1 (A) and CD68 (B)
immunoreactivities in synovium from a patient with osteoarthritis (OA).
Immunoreactivities both for TRPV1 (green) and for CD68 (red)
colocalise to mononuclear cells within the synovial lining and sublining
regions (arrows). Occasional CD68 immunoreactive cells do not display
TRPV1 immunoreactivity (arrowheads). L: surface of synovial lining.
Double ﬂuorescence immunohistochemistry. Scale bar=50 μm.
(C) Box and whisker plots showing increased abundance of
TRPV1-immunoreactive cells in OA compared with non-arthritic
postmortem (PM) control synovium. **p=0.003. (D) Western blot
analysis of TRPV1 in membrane-enriched fractions of synovial from ﬁve
patients with OA. TRPV1 immunoreactivity was detected at
approximately 100 kDa in lanes 1, 3, 4 and 5.
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JNJ-17203212 (0.075 mg and 0.15 mg/100 μL) close to the
ipsilateral knee joint inhibited mechanically evoked responses of
knee joint afferents (ﬁgure 3A; p<0.0001, two-way ANOVA
Bonferroni’s post hoc tests, n=11) in MIA-treated rats. In add-
ition, the lowered mechanical thresholds of joint afferents in
MIA-treated rats were reversed by JNJ-17203212 to the control
values seen in saline-treated rats (ﬁgure 3C). In saline-treated
rats, mechanically evoked responses of afferent ﬁbres (frequency
of evoked ﬁring and thresholds) were not altered by
JNJ-17203212 (ﬁgure 3B, C; n=10). Collectively these data
indicate the presence of a tonic activation of joint TRPV1 in the
model of OA pain, but not in control rats. Administration of
vehicle (2.5% and 5% ethanol, 10% Tween 80 in saline) did not
alter mechanically evoked responses of joint afferents in either
MIA-treated rats or saline-treated rats (see online supplementary
ﬁgure S6A,B). Note JNJ-17203212 signiﬁcantly attenuated
Figure 2 Endogenous transient receptor potential vanilloid 1 (TRPV1) activation at the level of the joint contributes to pain. (A) Intra-articular
administration of JNJ-17203212 signiﬁcantly attenuated weight-bearing asymmetry compared with intra-articular vehicle (3% Tween 80, 0.5% EtOH
in saline) in rats 14 days post-mono-iodoacetate (MIA) injection (n=11/9 rats) and to a similar degree as systemic (intra-peritoneal (i.p))
JNJ-17203212. Vehicle effects following intra-articular and i.p administration were not signiﬁcantly different; for clarity, intra-articular vehicle is
presented. Data are presented as mean±SEM and analysis used a two-way analysis of variance (ANOVA) with a Bonferroni’s post hoc test
(weight-bearing) or Mann–Whitney test (allodynia). *p<0.05 between i.art JNJ-17203212 and i.art vehicle. $p<0.05 between i.p JNJ-17203212 and
i.art vehicle. (B) Levels of the endogenous TRPV1 ligand 12-hydroxy-eicosatetraenoic acid were signiﬁcantly greater in joint tissue from MIA-treated
rats compared with saline-treated rats (p<0.05, Mann–Whitney; n=8 rats per group). (C) Stimulus–response curves of joint afferents to mechanical
von Frey monoﬁlament stimulation (0.16–15g) applied to the centre of the receptive ﬁeld in MIA-treated and saline-treated rats at day 14
post-injection. There was a signiﬁcant leftward shift in the stimulus–response curve in MIA-treated rats compared with saline-treated rats (**p<0.01,
n=30/37 MIA/saline, respectively). Data are displayed at mean±SEM. Analysis used a two-way ANOVA with Bonferroni’s post hoc test. (D) Close
intra-arterial administration of the TRPV1 agonist capsaicin (5–10 μM) increased (sensitised) mechanically evoked responses of joint afferents in
saline-treated rats. A signiﬁcant increase in the frequency of ﬁring was observed with 5 μM capsaicin in 40% (8/20) of ﬁbres in saline-treated rats
(***p<0.001, n=8). Data are displayed at mean±SEM. Analysis used a two-way ANOVA with Bonferroni’s post hoc test. (E) Close intra-arterial
administration of capsaicin (5 and 10 μM) signiﬁcantly reduced mechanical thresholds of 45% (9/20) of joint afferents in saline-treated rats (n=9).
Horizontal bars represent median values and analysis used a Mann–Whitney test, *p<0.05.
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capsaicin-evoked knee afferent ﬁring28 (see online supplemen-
tary ﬁgure S7).
No functional upregulation of TRPV1 in the spinal cord in
the model of OA pain
Given the known role of TRPV1 in the spinal processing of
noxious inputs and that spinal neuronal responses are facilitated
at 28 days in this model of OA,22 the ﬁnal series of experiments
investigated whether spinal TRPV1 is functionally upregulated in
this model of OA pain. Consistent with previous reports, TRPV1
immunoreactivity was detected in the superﬁcial laminae (I–II) of
the dorsal horn of the spinal cord (ﬁgure 4A B). There was a
bilateral increase in the mean total area of dorsal horn TRPV1
immunoreactivity in MIA–treated rats, at both days 14 and 28,
compared with saline-treated rats (ﬁgure 4C). The absence of
staining in the negative control conﬁrmed the speciﬁcity of
detected immunoreactivity.
Spinal electrophysiological experiments were then undertaken
to determine whether the increase in spinal TRPV1 immunoreac-
tivity has a functional consequence on neuronal responses in the
MIA model. Spinal administration of JNJ-17203212 (37.5 and
75 mg) produced a similar dose-related inhibition of noxious (15,
26 and 60 g) mechanically evoked responses of dorsal horn
WDR neurones in saline-treated rats (ﬁgure 5A) and MIA-treated
rats (at 14 and 28 days) (ﬁgures 5B,C). Spinal administration of
vehicle did not signiﬁcantly alter mechanically evoked responses
of WDR neurones in day 28 MIA-treated rats (ﬁgure 5D). These
data suggest that despite the increased expression of TRPV1 in
the spinal cord, there is no increase in the contribution of spinal
TRPV1 to noxious-evoked responses of spinal neurones in the
model of OA pain. In keeping with this ﬁnding, levels of
the endogenous TRPV1 ligand 12-HETE were comparable in the
ipsilateral spinal cords of MIA-treated and saline-treated
rats (median: MIA=17.4 pmol/g; range=5.65–33.58 pmol/g;
Figure 3 Blockade of peripheral transient receptor potential vanilloid 1 ablates afferent sensitisation in mono-iodoacetate (MIA) model. (A) Close
intra-arterial administration of JNJ-17203212 (0.075 mg, 0.15 mg/100 μL) signiﬁcantly reduced the frequency of mechanically evoked ﬁring of joint
afferents in MIA-treated rats (p<0.0001, n=11). (B) By contrast, JNJ-17203212 did not alter mechanically evoked responses of joint afferents in
saline-treated rats (n=10). Data are displayed at mean±SEM and analysis used a two-way analysis of variance (ANOVA) with Bonferroni’s post hoc
test. (C) Mechanical thresholds in MIA-treated rats were signiﬁcantly lower than saline-treated rats (p<0.001, n=11). Close intra-arterial injection of
JNJ-17203212 (0.15 mg/100 μL) reversed the lowered mechanical thresholds of joint afferents in MIA-treated rats (p<0.001, n=11). Mechanical
thresholds in MIA-treated rats which received JNJ-17203212 (0.15 mg/100 μL) were not statistically different from control (pre-drug) thresholds in
saline-treated rats (n=10). Bars represent median values and analysis used the Kruskal–Wallis test. ns, not signiﬁcant. *p<0.05, **p<0.01,
***p<0.001.
Figure 4 Transient receptor potential vanilloid 1 (TRPV1) immunoreactivity in the spinal cord. TRPV1 immunoﬂuorescence detected in superﬁcial
dorsal horn (10× magniﬁcation) in rat lumbar (L3–L5) spinal cord at day 28 post-intra-articular injection of saline (A) or mono-iodoacetate (MIA) (B).
Minimum and maximum brightness values were altered (32.01 min and 90.14 max) using Image J so as to highlight the area of TRPV1 positive
staining. (C) Quantiﬁcation of TRPV1 immunoﬂuorescence in superﬁcial dorsal horn of spinal cord taken from rats at 14 or 28 days following
intra-articular injection of MIA and at day 28 following intra-articular injection of saline. Data are expressed as mean and SEM (n=5 per group).
Analysis used a two-way analysis of variance (ANOVA) with a Bonferroni’s post hoc test. *p<0.05 and ***p<0.001 compared with saline treatment
and ###p<0.001 between day 14 and day 28 MIA treatment.
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saline=15.78 pmol/g, range=8.56–23.13 pmol/g, n=8 per
group).
DISCUSSION
Here we report new clinical evidence for a functional upregula-
tion of joint TRPV1 associated with OA, and preclinical evi-
dence that this channel contributes to altered pain responses in
an experimental model of OA. Our data from patients with OA
knee pain undergoing TKR surgery demonstrate an increase in
TRPV1 protein both in OA and in RA synovia compared with
non-arthritic PM controls. This increased expression of TRPV1
protein was associated with macrophage inﬁltration, indicating
that non-neuronal cells may contribute a large proportion of
synovial TRPV1. Preclinical studies revealed new evidence that
joint levels of an endogenous ligand for TRPV1, 12-HETE,
were elevated in this model of OA pain and that local pharma-
cological blockade of TRPV1 attenuated OA-induced joint affer-
ent sensitisation and pain responses. The outcomes of these
electrophysiological and behavioural studies support our
hypothesis that targeting TRPV1 in the diseased joint may
provide an alternative strategy for treating OA pain in the
absence of changes in core body temperature.
Clinical studies measuring pain pressure thresholds report
sensitisation of the OA joint.5 6 29 Clinically relevant animal
models of OA are essential for the identiﬁcation of the mechan-
isms which lead to this sensitisation seen clinically. As well as
mimicking the common features of human OA joint pathology
and associated pain behaviour,21 22 the MIA model of OA also
exhibits sensitisation of joint afferents.24 30 31 Here we report
new evidence that peripheral TRPV1 has a functional role in the
maintenance of OA-induced joint afferent sensitisation, which is
consistent with the role of TRPV1 in afferent mechanical sensi-
tisation during visceral32 and cutaneous inﬂammation.33 Local
blockade of TRPV1 reversed the sensitisation of knee joint affer-
ents, restored evoked responses of these afferents to control
values in the model of OA pain and attenuated pain behaviour
(weight-bearing asymmetry) to an extent comparable with the
effect of systemic injection of the TRPV1 antagonist. These
novel ﬁndings suggest that the knee joint is an important site of
action of TRPV1 antagonists and may contribute to the inhibi-
tory effects of systemic TRPV1 antagonists on pain responses in
models of OA.8–11
Multiple mechanism(s), including increased expression and/or
sensitisation of TRPV1 and increased levels of endogenous
ligands, may lead to a heightened contribution of peripheral
TRPV1 to somatosensory processing in OA. The increase in
abundance of TRPV1 protein in the synovium from OA patients
undergoing TKR was predominantly colocalised with CD68, a
marker for macrophages, which precluded the characterisation
of possible changes in TRPV-1 abundance in sensory nerves
within the synovium itself. TRPV1 expression by mononuclear
cells and ﬁbroblasts has previously been reported34 and this
ﬁnding is consistent with increased macrophage inﬁltration in
OA synovium.26 Collectively our data suggest that the increased
TRPV1 abundance in arthritic synovium results from inﬂamma-
tory cell hyperplasia rather than increased expression by resi-
dent synovial cells. Post-transcriptional modiﬁcations of TRPV1
may also alter protein turnover35 and contribute to the altered
expression of TRPV1 protein in arthritic synovium. The expres-
sion of TRPV1 by macrophages in OA is likely to produce
Figure 5 Effect of spinal
JNJ-17203212 on evoked responses of
wide dynamic range (WDR) neurones.
JNJ-17203212 signiﬁcantly and
dose-relatedly inhibited noxious
mechanically evoked responses of
dorsal horn WDR neurones (15, 26 and
60g) in saline-treated rats (n=7 rats) at
28 days post-injection (A) and in
mono-iodoacetate (MIA)-treated rats at
14 (n=9 rats) and 28 days (n=8 rats)
post-injection (B and C). No signiﬁcant
effect of the drug was noted on
non-noxious mechanically evoked
responses (8 and 10g) in any of the
treatment groups. (D) Spinal
administration of vehicle did not
signiﬁcantly affect mechanically evoked
responses in day 28 MIA-treated rats
(n=7 rats). Data are displayed at mean
±SEM. Analysis used two-way analysis
of variance (ANOVA) with Bonferroni’s
post hoc test; *p<0.05, **p<0.01 and
***p<0.001.
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proinﬂammatory effects,34 similar to those reported for OA syn-
ovial ﬁbroblasts where TRPV1 activation promotes the release
of interleukin 6,36 which can sensitise joint afferent ﬁbres.37
Clinical data suggest that increased expression of TRPV1 may
be associated with synovitis, which is a feature of human OA
and the MIA model of OA. The precise contribution and
mechanisms by which synovitis may mediate OA pain remain
uncertain, and the balance between inﬂammatory and non-
inﬂammatory mechanisms may differ between patients and over
time. As such, peripheral analgesic actions of TRPV1 antagonists
may be most pronounced in patients whose pain is associated
with synovitis. Selective recruitment of patients without an
inﬂammatory component to their pain into clinical trials of
TRPV1 antagonists may conceal potential beneﬁts in other
patient groups.
TRPV1 protein expression is upregulated in the cell bodies of
afferent ﬁbres innervating the joint in a model of OA pain13 and
can be activated by a wide range of endogenous bioactive lipids.7
38 12-HETE is an endogenous TRPV1 ligand known to increase
the ﬁring of afferent ﬁbres via TRPV1 activation.39 Here we
report that endogenous levels of 12-HETE are elevated in the
knee joint, but not the DRGs or spinal cord, in the MIA model
of OA pain, providing a plausible mechanism by which TRPV1
function is facilitated at this level. Further, our RT-PCR data indi-
cate increased TRPV1 mRNA expression in the synovium follow-
ing MIA. These ﬁndings and the demonstration that
intra-articular injection of a TRPV1 antagonist blocks established
OA pain behaviour (weight-bearing asymmetry) in the MIA
model of OA strongly support peripheral TRPV1 making an
important functional contribution to the maintenance of OA
pain responses. It is well established that systemic administration
of TRPV1 antagonists attenuates pain responses in the MIA
model8–11 but at the expense of on-target-mediated hyperther-
mia,10 40 which may inﬂuence therapeutic potential. Here we
demonstrate that intra-articular administration of an analgesic
dose of the TRPV1 antagonist does not alter core body tempera-
ture, suggesting that the localised delivery of this class of drugs
may afford therapeutic beneﬁt in the absence of hyperthermia.
As well as playing a role as an integrator of noxious stimuli in
the periphery, TRPV1 is present on the central endings of the
sensory afferents in the spinal cord and contributes to spinal noci-
ceptive processing.41 42 Analytical and pharmacological evidence
presented herein indicates that the functional role of spinal
TRPV1 is unaltered in the model of OA pain, despite increased
TRPV1 immunoreactivity in the superﬁcial laminae of the dorsal
horn in the model of OA pain. The bilateral increase in TRPV1
expression suggests contralateral activation at the spinal level fol-
lowing MIA, consistent with previous ﬁndings that unilateral arth-
ritis can induce bilateral changes in spinal neuronal phenotype.43
In summary, the increased abundance of TRPV1 in our clin-
ical arthritic synovium samples along with the polymorphisms
in TRPV1 associated with human OA pain12 emphasise the rele-
vance of TRPV1 to human OA pain. Our novel experimental
evidence for increased functional role of TRPV1 at the level of
the joint in a model of OA pain and the demonstration that
blockade of joint TRPV1 ablates sensory afferent sensitisation
and pain behaviour support future targeted site-speciﬁc investi-
gations of the therapeutic potential of TRPV1 for OA pain asso-
ciated with synovitis.
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